NASDAQ:ENDP - Endo International Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.21 -0.28 (-2.08 %) (As of 11/12/2018 12:30 PM ET)Previous Close$13.49Today's Range$13.00 - $13.5552-Week Range$5.27 - $18.50Volume140,575 shsAverage Volume5.26 million shsMarket Capitalization$3.02 billionP/E Ratio3.43Dividend YieldN/ABeta0.65 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Receive ENDP News and Ratings via Email Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ENDP Previous Symbol CUSIP29264F20 Webwww.endo.com Phone011-353-1268-2000 Debt Debt-to-Equity RatioN/A Current Ratio1.13 Quick Ratio0.91 Price-To-Earnings Trailing P/E Ratio3.43 Forward P/E Ratio4.89 P/E Growth1.26 Sales & Book Value Annual Sales$3.47 billion Price / Sales0.85 Cash Flow$8.2050 per share Price / Cash1.61 Book Value($0.98) per share Price / Book-13.48 Profitability EPS (Most Recent Fiscal Year)$3.84 Net Income$-2,035,430,000.00 Net Margins-37.82% Return on Equity1,348.52% Return on Assets6.02% Miscellaneous Employees3,039 Outstanding Shares223,930,000Market Cap$3.02 billion OptionableOptionable Endo International (NASDAQ:ENDP) Frequently Asked Questions What is Endo International's stock symbol? Endo International trades on the NASDAQ under the ticker symbol "ENDP." How were Endo International's earnings last quarter? Endo International PLC (NASDAQ:ENDP) issued its earnings results on Thursday, November, 8th. The company reported $0.71 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.59 by $0.12. The firm had revenue of $745 million for the quarter, compared to analysts' expectations of $694.93 million. Endo International had a positive return on equity of 1,348.52% and a negative net margin of 37.82%. The company's revenue was down 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.91 earnings per share. View Endo International's Earnings History. When is Endo International's next earnings date? Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Endo International. What guidance has Endo International issued on next quarter's earnings? Endo International issued an update on its FY18 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of $2.65-2.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.60. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.81 billion.Endo International also updated its FY 2018 guidance to $2.65-2.75 EPS. What price target have analysts set for ENDP? 18 brokerages have issued twelve-month target prices for Endo International's stock. Their predictions range from $8.50 to $26.00. On average, they anticipate Endo International's share price to reach $15.70 in the next year. This suggests a possible upside of 20.5% from the stock's current price. View Analyst Price Targets for Endo International. What is the consensus analysts' recommendation for Endo International? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International. What are Wall Street analysts saying about Endo International stock? Here are some recent quotes from research analysts about Endo International stock: 1. According to Zacks Investment Research, "Endo is in the process of redefining its business, given the persistent decline in the generic business and withdrawal of opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. Sales of Xiaflex are being driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Revenues from the sterile injectables business are being driven by the continued growth of Adrenalin. The business is poised to become Endo's core business. While the turnaround might take time, the company seems to be on the right track. Shares have outperformed the industry in the year so far. However, the generic business is expected to face further challenges. Competition is expected to intensify further in 2018." (9/24/2018) 2. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018) 3. Cantor Fitzgerald analysts commented, ". We are raising our 12 month PT for ENDP shares to $12 from $7. The increase in our PT is driven by multiple expansion (from 8x to 9x 2019 EV/EBITDA versus 10x for the comps). We think this is deserved since generic drug pricing has stabilized for ENDP, according to the company, and we are optimistic that ENDP could report positive data for CCH to treat cellulite as early as the end of this year versus its official guidance of 2019. The following points support our view." (7/23/2018) 4. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018) Has Endo International been receiving favorable news coverage? Headlines about ENDP stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Endo International earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. Are investors shorting Endo International? Endo International saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 26,028,247 shares, a drop of 13.5% from the October 15th total of 30,093,550 shares. Based on an average daily trading volume, of 4,798,912 shares, the days-to-cover ratio is presently 5.4 days. Currently, 13.0% of the shares of the stock are short sold. View Endo International's Current Options Chain. Who are some of Endo International's key competitors? Some companies that are related to Endo International include Bausch Health Companies (BHC), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), Nektar Therapeutics (NKTR), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY) and Catalent (CTLT). Who are Endo International's key executives? Endo International's management team includes the folowing people: Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)Mr. Blaise Coleman, Exec. VP & CFO (Age 44)Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 61) Who are Endo International's major shareholders? Endo International's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.12%), Alps Advisors Inc. (0.21%), Arizona State Retirement System (0.13%), Globeflex Capital L P (0.09%), Comerica Bank (0.09%) and Capital Growth Management LP (0.06%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International. Which institutional investors are selling Endo International stock? ENDP stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, Price Capital Management Inc., Gamco Investors INC. ET AL, Alps Advisors Inc., Gabelli Funds LLC, Comerica Bank, Russell Investments Group Ltd. and Arizona State Retirement System. View Insider Buying and Selling for Endo International. Which institutional investors are buying Endo International stock? ENDP stock was acquired by a variety of institutional investors in the last quarter, including Capital Growth Management LP, Commonwealth Bank of Australia, Meeder Asset Management Inc., Bank of New York Mellon Corp, O Shaughnessy Asset Management LLC, Globeflex Capital L P, Affinity Investment Advisors LLC and Toronto Dominion Bank. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International. How do I buy shares of Endo International? Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endo International's stock price today? One share of ENDP stock can currently be purchased for approximately $13.0250. How big of a company is Endo International? Endo International has a market capitalization of $3.02 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe. What is Endo International's official website? The official website for Endo International is http://www.endo.com. How can I contact Endo International? Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected] MarketBeat Community Rating for Endo International (NASDAQ ENDP)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 825 (Vote Outperform)Underperform Votes: 673 (Vote Underperform)Total Votes: 1,498MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/12/2018 by MarketBeat.com StaffFeatured Article: What are the risks of holding treasury bonds?